Equal-WT
WhaleScore 2.0
?
RTW INVESTMENTS, LP
- HTTP://WWW.RTWFUNDS.COM
- HTTPS://WWW.LINKEDIN.COM/COMPANY/RTW-INVESTMENTS-LLC/
- https://x.com/rtwlp
- https://www.instagram.com/rtwinvestmentslp/
RTW Investments is based out of New York. RTW Investments is a hedge fund with 10 clients and discretionary assets under management (AUM) of $9,806,112,769 (Form ADV from 2025-03-28). Their last reported 13F filing for Q3 2025 included $8,116,139,085 in managed 13F securities
and a top 10 holdings concentration of 52.59%. RTW Investments's largest holding is Madrigal Pharmaceuticals Inc with shares held of 1,993,687. Whalewisdom has at least 52 13F filings, 48 13D filings, 372 13G filings, and 74 Form 4 filings
Business Description
Based on the provided documents, Item 4 discusses the advisory business of RTW Investments, LP.
Unfortunately, the content of Item 4 is not included in the provided documents, so a summary of the advisory business cannot be provided.
Investment Strategy
Each Company Series will constitute a separate pool of investment assets and function as a separate limited liability company. RTW will source and perform due diligence on investment opportunities for each Company Series, and will provide investment advisory services to, and manage the investment decisions of, each Company Series.
Each Company Series is expected to have a different investment strategy. In certain cases, the same position may be held by more than one Company Series and/or more than one Company Series may have a substantially similar investment strategy to another Company Series, in which case the various Company Series may trade pari passu to one another to the extent determined by RTW and as further disclosed in the applicable Supplement for the.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2025-09-30
Top Buys (13F)
| Name | % Change |
|---|---|
| RNA Avidity Biosciences, | 2.21% |
| XNCR Xencor Inc | 0.63% |
| COGT Cogent Biosciences I | 0.61% |
| TARS Tarsus Pharmaceutica | 0.53% |
| GH Guardant Health Inc | 0.51% |
2025-09-30
Top Sells (13F)
| Name | % Change |
|---|---|
| VRNA Verona Pharma Plc | 4.11% |
| NTRA Natera Inc | 2.27% |
| ZLAB Zai Lab Ltd | 1.8% |
| ALKS Alkermes Plc | 1.29% |
| SYK Stryker Corp | 1.1% |
2025-09-30
13F Holdings Summary
| Name | % of Portfolio |
|---|---|
| MDGL Madrigal Pharmaceuti | 11.27% |
| ARGX Argenx SE ADS ADR | 6.12% |
| RNA Avidity Biosciences, | 6.11% |
| PTCT PTC Therapeutics Inc | 5.86% |
| INSM Insmed Inc | 5.47% |
2025-09-30
13F Activity
| Market Value | $8.12b, Prior: $7.02b |
| Inflows (Outflows) as % of Total MV | (-9.0053)% |
| New Purchases | 10 stocks |
| Added To | 17 stocks |
| Sold out of | 9 stocks |
| Reduced holdings in | 12 stocks |
| Top 10 Holdings % | 52.59% |
| Turnover %[1] | 22.89% |
| Turnover Alt %[2] | 6.44% |
| Time Held Top 20 | 8 quarters |
| Time Held Top 10 | 3.8 quarters |
| Time Held All | 9.62 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2025-09-30
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2025-09-30
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2025-09-30